IP Library Granted Patent US 8,313,742
Granted Patent B2
US 8,313,742 · App. 10/109,946 · Granted Nov 20, 2012

Cell-containing bone graft material

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,313,742
App. No.
10/109,946
Granted
Nov 20, 2012
Kind
B2
Abstract

This invention relates to a musculoskeletogenic MSG graft composite made from whole bone marrow aspirate BMA having native levels of musculoskeletal progenitor cells MSPCs, comprising: a) a suspension of fractionated BMA comprising: i) MSPCs present at a level greater than their native level in whole BMA, and ii) red blood cells RBCs present at a level less than their native level in whole BMA, and b) a porous sterile matrix having an average pore size of at least 20 μm.

Claims (15)

1. A musculoskeletogenic (MSG) graft composite made from whole bone marrow aspirate (BMA), the graft composite consisting of:

a) a physiologic fraction obtained from centrifugation of whole BMA, consisting essentially of:

i) musculoskeletal progenitor cells (MSPCs) at a level greater than their native level in whole BMA, and

ii) red blood cells (RBCs) derived from BMA at a level less than their native level in whole BMA,

iii) platelets at a level greater than their native level in whole BMA, and

b) a porous sterile matrix having an D 50 average pore size of at least 20 μm,

c) a platelet release agent added in an amount sufficient to cause the release of growth factors from BMA-derived platelets,

wherein the (a) physiologic fraction of BMA and the (c) platelet release agent are contained within the (b) porous sterile matrix, thereby causing release of growth factors from the BMA-derived platelets,

wherein the matrix is demineralized bone matrix and the platelet release agent is thrombin.

2. The composite of claim 1 wherein the MSPCs are present in the physiologic fraction at a level 2 times greater than their native level in whole BMA.

3. The composite of claim 1 wherein the MSPCs are present in the physiologic fraction at a level 5 times greater than their native level in whole BMA.

4. The composite of claim 1 wherein the RBCs derived from BMA are present in the physiologic fraction at a level less than 20% their native level in whole BMA.

5. The composite of claim 1 wherein the porous matrix has a D 50 average pore size of at least 50 μm.

6. The composite of claim 1 wherein the porous matrix has a D 50 average pore size of at least 100 μm.

7. The composite of claim 1 wherein the ratio of the physiologic fraction to the matrix is between 1:1 (v/v) and 1:20 (v/v).

Assignments (3)
CHANGE OF NAME Recorded May 6, 2013
From: DEPUY SPINE, INC.
To: DEPUY SPINE, LLC
Reel/Frame 030352/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2013
From: DEPUY SPINE, LLC
To: HAND INNOVATIONS LLC
Reel/Frame 030352/0709 →
CHANGE OF NAME Recorded May 6, 2013
From: HAND INNOVATIONS LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 030352/0722 →